Clinical Trial

Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 18, 2023 (before its estimated January 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study observes the safety and efficacy of Azacitidine (AZA) combined with ruxolitinib to treat higher-risk Myelodysplastic Syndromes∕Myeloproliferative Neoplasms(MDS/MPN)
Trial Details
NCT Number NCT05817955
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Collaborators: Affiliated Hospital of Jiangsu University, The Second Hospital of Nanjing Medical University, Jiangning Hospital Affiliated to Nanjing Medical University
Conditions MDS/MPN
Enrollment 50 participants
Start Date 2022-11-01
Primary Completion 2025-01-01 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2023-04-18